Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cetuximab + cisplatin + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination involves **tislelizumab**, an anti-PD-1 monoclonal antibody that enhances T-cell function by blocking PD-1 signaling; **cetuximab**, an EGFR inhibitor used in treating colorectal and head and neck cancers; **cisplatin**, a platinum-based chemotherapy agent; and **nab-paclitaxel**, a formulation of paclitaxel that improves solubility and delivery. The combination is likely used for advanced cancers, leveraging both immunotherapy and chemotherapy.
02
Targets
DNAEGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on tislelizumab + cetuximab + cisplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cetuximab + cisplatin + nab-paclitaxel.